142 related articles for article (PubMed ID: 28012085)
1. The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients.
Li Y; Kurian AW; Bondarenko I; Taylor JMG; Jagsi R; Ward KC; Hamilton AS; Katz SJ; Hofer TP
Breast Cancer Res Treat; 2017 Feb; 161(3):587-595. PubMed ID: 28012085
[TBL] [Abstract][Full Text] [Related]
2. Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry.
Henry NL; Braun TM; Ali HY; Munir K; Silver SM; Gorski DH; Breslin TM; Griggs JJ
Cancer; 2017 May; 123(6):948-956. PubMed ID: 27787892
[TBL] [Abstract][Full Text] [Related]
3. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
Chen C; Dhanda R; Tseng WY; Forsyth M; Patt DA
J Oncol Pract; 2013 Jul; 9(4):182-7. PubMed ID: 23942918
[TBL] [Abstract][Full Text] [Related]
4. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
[TBL] [Abstract][Full Text] [Related]
5. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
6. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
[TBL] [Abstract][Full Text] [Related]
7. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
Jasem J; Fisher CM; Amini A; Shagisultanova E; Rabinovitch R; Borges VF; Elias A; Kabos P
J Natl Compr Canc Netw; 2017 Apr; 15(4):494-503. PubMed ID: 28404760
[No Abstract] [Full Text] [Related]
8. Adjuvant chemotherapy and survival outcome in node-negative breast cancer with a 21-gene recurrence score of 26-30.
Yang SP; Yao J; Zhou P; Lian CL; Wang J; Fang MX; Wu SG
Future Oncol; 2021 Jun; 17(17):2183-2192. PubMed ID: 33605163
[TBL] [Abstract][Full Text] [Related]
9. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
10. 21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes.
Tong Y; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
Sci Rep; 2019 Sep; 9(1):13123. PubMed ID: 31511599
[TBL] [Abstract][Full Text] [Related]
11. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
[TBL] [Abstract][Full Text] [Related]
12. Oncologists' influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer?
Katz SJ; Hawley ST; Bondarenko I; Jagsi R; Ward KC; Hofer TP; Kurian AW
Breast Cancer Res Treat; 2017 Oct; 165(3):751-756. PubMed ID: 28689364
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
[TBL] [Abstract][Full Text] [Related]
14. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
15. The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
Kuchel A; Robinson T; Comins C; Shere M; Varughese M; Sparrow G; Sahu A; Saunders L; Bahl A; Cawthorn SJ; Braybrooke JP
Br J Cancer; 2016 Mar; 114(7):731-6. PubMed ID: 26954715
[TBL] [Abstract][Full Text] [Related]
16. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
[TBL] [Abstract][Full Text] [Related]
17. Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy.
Enewold L; Geiger AM; Zujewski J; Harlan LC
Breast Cancer Res Treat; 2015 May; 151(1):149-56. PubMed ID: 25859924
[TBL] [Abstract][Full Text] [Related]
18. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
19. Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx.
Lee RM; Switchenko JM; Ho TB; Arciero CA; Bhave MA; Subhedar PD
Ann Surg Oncol; 2019 Oct; 26(10):3152-3158. PubMed ID: 31342377
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.
Friese CR; Li Y; Bondarenko I; Hofer TP; Ward KC; Hamilton AS; Deapen D; Kurian AW; Katz SJ
Cancer; 2017 Jan; 123(1):43-51. PubMed ID: 27775837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]